Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
81.40
+3.92 (5.06%)
At close: Dec 19, 2025, 4:00 PM EST
81.23
-0.17 (-0.21%)
After-hours: Dec 19, 2025, 7:48 PM EST
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts that cover Tarsus Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $76.56, which forecasts a -5.95% decrease in the stock price over the next year. The lowest target is $51 and the highest is $100.
Price Target: $76.56 (-5.95%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 3 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $100 | Buy | Initiates | $100 | +22.85% | Dec 9, 2025 |
| Mizuho | Mizuho | Buy Initiates $100 | Buy | Initiates | $100 | +22.85% | Nov 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $84 → $87 | Strong Buy | Maintains | $84 → $87 | +6.88% | Nov 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $72 → $88 | Strong Buy | Maintains | $72 → $88 | +8.11% | Oct 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | -11.55% | May 27, 2025 |
Financial Forecast
Revenue This Year
452.34M
from 182.95M
Increased by 147.24%
Revenue Next Year
692.58M
from 452.34M
Increased by 53.11%
EPS This Year
-1.53
from -3.07
EPS Next Year
1.82
from -1.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 467.5M | 815.5M | ||||
| Avg | 452.3M | 692.6M | ||||
| Low | 433.6M | 592.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 155.5% | 80.3% | ||||
| Avg | 147.2% | 53.1% | ||||
| Low | 137.0% | 30.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.38 | 3.37 | ||||
| Avg | -1.53 | 1.82 | ||||
| Low | -2.05 | 0.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.